Maxwell Biosciences

Maxwell Biosciences

Biotechnology, 3809 Juniper Trce Ste 102, Austin, Texas, 78738, United States, 11-50 Employees

maxwellbiosciences.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 51********

Who is MAXWELL BIOSCIENCES

Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to ...

Read More

map
  • 3809 Juniper Trce Ste 102, Austin, Texas, 78738, United States Headquarters: 3809 Juniper Trce Ste 102, Austin, Texas, 78738, United States
  • 2016 Date Founded: 2016
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 1731

checked-icon Does something look wrong? Fix it. | View contact records from MAXWELL BIOSCIENCES

Maxwell Biosciences Org Chart and Mapping

Employees

Meagan Stone

Senior Director of Operations

Sheetal Vali

Sr. Director of Drug Development

Tony Verco

Chief Medical Officer

Donald Treacy

SVP, Development Operations

Beth Burnside

Sr. Vice President R&D Strategy

Edward Rudnic

Chief Operating Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Maxwell Biosciences

Answer: Maxwell Biosciences's headquarters are located at 3809 Juniper Trce Ste 102, Austin, Texas, 78738, United States

Answer: Maxwell Biosciences's phone number is 51********

Answer: Maxwell Biosciences's official website is https://maxwellbiosciences.com

Answer: Maxwell Biosciences's revenue is $1 Million to $5 Million

Answer: Maxwell Biosciences's SIC: 1731

Answer: Maxwell Biosciences has 11-50 employees

Answer: Maxwell Biosciences is in Biotechnology

Answer: Maxwell Biosciences contact info: Phone number: 51******** Website: https://maxwellbiosciences.com

Answer: Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMERTM brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMERTM brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's multi-asset, multi-target anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access